Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CA-125 in gynecological malignancies.

W Meier1, P Stieber, A Fateh-Moghadam

  • 1Department of Obstetrics and Gynecology, Klinikum Grosshadern, University of Munich, West Germany.

European Journal of Cancer & Clinical Oncology
|June 1, 1987
PubMed
Summary

Cancer antigen 125 (CA-125) shows high sensitivity for ovarian cancer detection. Elevated CA-125 serum levels accurately predict residual tumor presence at second-look surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.

British journal of cancer·2015
Same author

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.

British journal of cancer·2013
Same author

Cytokeratin serum biomarkers in patients with colorectal cancer.

Anticancer research·2012
Same author

Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer.

Current oncology (Toronto, Ont.)·2012
Same author

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?

European journal of medical research·2011
Same author

Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.

European journal of gynaecological oncology·2010

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Clinical Chemistry

Background:

  • CA-125 is a tumor marker frequently detected in epithelial ovarian carcinomas.
  • Radioimmunoassay using monoclonal antibodies allows CA-125 serum measurement.
  • CA-125 exhibits high sensitivity but low specificity for ovarian cancer, particularly serous cystadenocarcinoma.

Purpose of the Study:

  • To investigate the correlation between CA-125 serum levels and histological findings during second-look operations in ovarian cancer patients.
  • To assess the utility of CA-125 in verifying complete remission after chemotherapy.

Main Methods:

  • Serum CA-125 levels were measured using radioimmunoassay.
  • Second-look operations were performed after six cycles of chemotherapy in 22 patients.

Related Experiment Videos

  • Histological examination of surgical specimens determined the presence and size of residual tumor.

    • Main Results:

    • Active tumor was identified in 16 out of 22 patients.
    • In patients with elevated CA-125, residual tumor was consistently confirmed histologically.
    • No false-positive CA-125 results were observed; residual tumor <1 cm was found in 6 patients with negative CA-125 values.

    Conclusions:

    • Elevated CA-125 serum levels are highly predictive of residual ovarian cancer at second-look surgery.
    • Second-look operation is essential for verifying complete remission in ovarian cancer patients.
    • CA-125 is a sensitive indicator for detecting residual disease, aiding in treatment response assessment.